DHRS9

Across TCGA pan-cancer cohorts, DHRS9 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated DHRS9 data layer compared with 20 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher DHRS9 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated DHRS9 expression acts as an unfavorable survival marker, although some lineages such as HNSC and LUAD show a favorable association.

PDAC, HNSC, and LUAD are the cancer types where DHRS9 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Tertile	II,III,IV	0.301	0.583	.004	32	view →
HNSC	OS	Tertile	IV	0.900	0.661	.038	6	view →
LUAD	DFS	Tertile	II,III,IV	0.746	0.406	.020	2	view →
CCRCC	DFS	Tertile	All	1.000	0.392	.024	2	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

DHRS9–PDAC (DFS)

Open the PDAC breakdown →